The Hourigan Lab focuses on the detection of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)


Check out our papers

Seminars in Hematology Special Issue on AML

F1000 Profile


Our Completed Clinical Trials:

PD-AML  Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia (Photo)
PEARL Personalized Early Assessment of Response in Acute Myeloid Leukemia  (Photo)